Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 17
2003 12
2004 14
2005 20
2006 19
2007 18
2008 19
2009 10
2010 11
2011 20
2012 14
2013 11
2014 21
2015 20
2016 16
2017 20
2018 25
2019 14
2020 17
2021 17
2022 10
2023 12
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).
Yabe D, Shiki K, Homma G, Meinicke T, Ogura Y, Seino Y; EMPA-ELDERLY Investigators. Yabe D, et al. Among authors: seino y. Diabetes Obes Metab. 2023 Dec;25(12):3538-3548. doi: 10.1111/dom.15249. Epub 2023 Aug 25. Diabetes Obes Metab. 2023. PMID: 37622398 Clinical Trial.
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
Chan JCN, Lim LL, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, Lau ESH, Eliasson B, Kong APS, Ezzati M, Aguilar-Salinas CA, McGill M, Levitt NS, Ning G, So WY, Adams J, Bracco P, Forouhi NG, Gregory GA, Guo J, Hua X, Klatman EL, Magliano DJ, Ng BP, Ogilvie D, Panter J, Pavkov M, Shao H, Unwin N, White M, Wou C, Ma RCW, Schmidt MI, Ramachandran A, Seino Y, Bennett PH, Oldenburg B, Gagliardino JJ, Luk AOY, Clarke PM, Ogle GD, Davies MJ, Holman RR, Gregg EW. Chan JCN, et al. Among authors: seino y. Lancet. 2021 Dec 19;396(10267):2019-2082. doi: 10.1016/S0140-6736(20)32374-6. Epub 2020 Nov 12. Lancet. 2021. PMID: 33189186 Review. No abstract available.
Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
Yabe D, Shiki K, Suzaki K, Meinicke T, Kotobuki Y, Nishida K, Clark D, Yasui A, Seino Y. Yabe D, et al. Among authors: seino y. BMJ Open. 2021 Apr 7;11(4):e045844. doi: 10.1136/bmjopen-2020-045844. BMJ Open. 2021. PMID: 33827843 Free PMC article. Clinical Trial.
Effect of Roxadustat on Thyroid Function in Patients With Renal Anemia.
Haraguchi T, Hamamoto Y, Kuwata H, Yamazaki Y, Nakatani S, Hyo T, Yamada Y, Yabe D, Seino Y. Haraguchi T, et al. Among authors: seino y. J Clin Endocrinol Metab. 2023 Dec 21;109(1):e69-e75. doi: 10.1210/clinem/dgad483. J Clin Endocrinol Metab. 2023. PMID: 37597171
Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y, Katagiri H, Hamamoto Y, Deenadayalan S, Navarria A, Nishijima K, Seino Y; PIONEER 9 investigators. Yamada Y, et al. Among authors: seino y. Lancet Diabetes Endocrinol. 2020 May;8(5):377-391. doi: 10.1016/S2213-8587(20)30075-9. Lancet Diabetes Endocrinol. 2020. PMID: 32333875 Clinical Trial.
Corrigendum.
Seino Y, Sasaki T, Fukatsu A, Ubukata M, Sakai S, Samukawa Y. Seino Y, et al. Curr Med Res Opin. 2015 Dec;31(12):2345. doi: 10.1185/03007995.2015.1093404. Epub 2015 Sep 22. Curr Med Res Opin. 2015. PMID: 26393294 No abstract available.
[Pancreatic polypeptide].
Fukuda K, Inagaki N, Seino Y. Fukuda K, et al. Among authors: seino y. Nihon Rinsho. 2005 Aug;63 Suppl 8:521-3. Nihon Rinsho. 2005. PMID: 16149567 Review. Japanese. No abstract available.
304 results